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Pyrazole carbohydrazidea b s t r a c t
Because there is no vaccine in clinical use, control of Leishmaniasis relies almost exclusively on chemo-
therapy and the conventional treatments exhibit high toxicity for patients and emerging drug resistance.
Recently, we showed that oral treatment with synthetic pyrazole carbohydrazide compounds induced
lower parasite load in draining lymph nodes and reduced skin lesion size without causing any toxic
effects in an experimental murine infection model with Leishmania amazonensis. In this study, CBA mice
were infected in the footpad with L. amazonensis and then orally treated with pyrazole carbohydrazides
derivatives, such as BrNO2, NO2Cl and NO2Br and their histopathological and immunological effects were
then investigated. Epidermis and dermis had lower levels of inﬂammatory inﬁltration compared to the
infected untreated control mice. In the dermis of treated animals, the numbers of vacuolated macro-
phages containing intracellular parasites were far lower than in infected untreated animals. In addition
to dermal macrophages, we also observed a mixed inﬂammatory inﬁltrate containing lymphocytes and
granulocyte cells. Lower numbers of B cells (B220+) and T lymphocytes (CD3+) were identiﬁed in the
lesions of treated mice compared with the untreated, infected mice. In draining lymph node cells, the
number of T lymphocytes (CD3+) was decreased, and the numbers of B cells (CD19+) and CD8+ T cells
were increased in infected mice, when compared with the non-infected control group. In additional,
we have shown that infected treated and untreated lymph node cells had similar levels of TGF-b and
IFN-c mRNA expression, whereas IL-4 was expressed at a lower level in the treated group. Increased
levels of the speciﬁc anti-Leishmania IgG2a or IgG3 antibody subclass were observed in NO2Cl or BrNO2-
treated group, respectively. Overall, our experimental ﬁndings suggest that pyrazole carbohydrazidesl@gmail.com (V.F. Amaral).
er OA license.
202 K.S. Charret et al. / Experimental Parasitology 133 (2013) 201–210exert modulation of IL-4 expression and B cell levels; however, further evaluation is required to deter-
mine the optimal treatment regime.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Leishmaniasis is a parasitic disease of the tropical and subtrop-
ical regions of the world, affecting about two million people per
year (Desjeux, 2004). The disease is expanding in Latin America
and is increasing among patients with HIV, including in Europe
(Cruz et al., 2006). Leishmaniases are caused by ﬂagellate protozoa
that are transmitted to humans by a sand ﬂy vector. When these
insects take a blood meal, they transmit the infectious forms of
the protozoa to the vertebrate host. The metacyclic promastigotes
then infect macrophages, where they remain in phagolysosomes
and differentiate into replicating amastigotes. The progression of
the disease depends on the nature of the host immune response,
as well as factors intrinsic to the parasite, which are expressed dif-
ferently among the species of Leishmania. The control of leishman-
iasis is very complex and depends on the variety of the Leishmania
parasite species, drug resistance and the side effects of the drugs
used (Ameen, 2010).
Despite their toxic properties and side effects, pentavalent anti-
monial compounds (Sbv) are still the ﬁrst-choice drugs for leish-
maniasis treatment (Andersen et al., 2005; Frézard et al., 2009).
However, the emerging resistance of Leishmania to Sbv compounds
limits its use (Herwaldt, 1999; Sundar and Murray, 2005). Other
compounds have been evaluated against Leishmania, such as
amphotericin B, rifampicin, pentamidine, aminosidine, miltefosine,
allopurinol, ketoconazole, metronidazole and other therapeutic ap-
proaches in different regions (Foti, 2001). The ideal anti-Leishmania
drug would be the one that eliminated the parasite and, at the
same time, modulated the host immune response.
The characterization of two distinct populations of CD4+ T cells,
Th1 and Th2 cells, in a mouse model of infection by Leishmania ma-
jor (Mosmann et al. 1986; Sacks and Noben-Trauth, 2002) enabled
some of the mechanisms associated with the resistance or suscep-
tibility of the host to be identiﬁed. Th1 responses are associated
with the cytokines IFN-c, IL-2 and TNF-a, with activating macro-
phages playing an important role. Th1 responses can induce cyto-
philic antibodies (IgG2a and IgG3) and/or delayed type
hypersensitivity as part of a protective immune response against
intracellular pathogens (Trinchieri, 1993). In contrast, Th2 re-
sponses are associated with IL-4, IL-5, IL-10, TGF-b and IL-13,
which stimulate the production of antibodies (IgG1 and IgE), the
activation of eosinophils and mast cells and the inhibition of some
macrophage functions (Coffman et al., 1988; Boom et al., 1990;
Fiorentino et al., 1991). Compounds that alter the cytokine micro-
environment can drives immune response to Th1 immunoprote-
tive response. Reducing the number of parasites can also reduce
the immunogenic stimulus that leads to the expansion of Th2 cells
during infection (Alexander et al., 1999).
Infection by Leishmania amazonensis causes progressive, non-
healing lesions in strains of mice resistant to L. major (McMahon-
Pratt and Alexander, 2004). Susceptible CBA mice infected with
L. amazonensis produce IL-4 and IL-10, in contrast to L. major-
infected CBA mice, which produce IFN-c and IL-10 (Lemos de
Souza et al., 2000). However, studies using C3H and C57BL/6 mice
showed that the pathogenesis of the disease caused by
L. amazonensis is due to a failure to mount a Th1 response, rather
than the development of a Th2 response (Afonso and Scott, 1993;
Jones et al., 2002; Ji et al., 2003).
In humans, IL-4 is associated with disease development (Kumar
et al., 2009). The cellular mechanisms responsible for thesusceptibility of mice to infection by L. amazonensis is still not
clear, although CD4+ T cells have been shown to play an important
role in the pathogenesis of the disease (Soong et al., 1997; Jones
et al., 2000). Other cell types also contribute to the development
of disease, including B cells and the antibodies they produce (Kima
et al., 2000).
Heterocyclic acyl hydrazones pyrazole is a structure with
diverse pharmacological activities (Duarte et al., 2007) and is,
therefore, of great interest for the treatment of leishmaniasis. The
1-(4-X-phenyl)-N’-[(4-Y-phenyl) methylene]-1H-pyrazole-4-
carbohydrazides are heterocyclic compounds which contain an
aromatic ring and a pyrazole hydrazone group. Analgesic, anti-
inﬂammatory and anti-thrombotic activities have been reported
for these acyl hydrazones compounds (Duarte et al., 2007). Some
studies have also demonstrated antitumor and antiviral activities
(Rostom et al., 2003). Pyrazole carbohydrazide derivatives showed
anti-parasitic activity in vitro against L. amazonensis promastigotes
and, to a lesser extent, Leishmania braziliensis and Leishmania chag-
asi, with no toxicity to murine macrophages (Bernardino et al.,
2006). These derivatives were tested in a murine model of infection
with L. amazonensis and showed a signiﬁcant therapeutic effect,
with no signs of liver or kidney toxicity (Charret et al., 2009). Based
on these data, in this study we correlated the treatment with
different pyrazole carbohydrazide derivatives with lesion
histopathology and immunological pattern in mice infected with
L. amazonensis.2. Materials and methods
2.1. Parasites
Leishmania amazonensis (MHOM/BR/77LTB0016 strain) was
maintained by animal passage and cryopreserved in liquid
nitrogen. Promastigotes were cultured in Schneider’s Drosophila
medium, pH 7.2 (Sigma, St. Louis, MO, USA), supplemented with
10–20% (v/v) heat-inactivated fetal calf serum (FCS). The character-
ization of the strains was performed using molecular techniques
such as isoenzyme electrophoresis (Grimaldi et al., 1987).2.2. Animals
Mice were acquired from the Núcleo de Animais de Laboratório
(NAL-UFF). Each experimental group consisted of ﬁve male
8-week-old CBA mice. The CBA strain was chosen because is
susceptible to infection with L. amazonensis and develop cutaneous
lesions, but do not demonstrate intense parasite dissemination, as
do BALB/c mice. The experiments were conducted using a protocol
approved by the Comissão de Ética no Uso de Animais-CEPA/UFF
(0090/09).2.3. Chemicals
The 1-(4-X-phenyl)-N0-[(4-Y-phenyl) methylene]-1H-pyrazole-
4-carbohydrazides (Fig. 1) with the substituents (1) Br–NO2
(X = Br, Y = NO2); (2) NO2–Cl (X = NO2, Y = Cl) and (3) NO2–Br
(X = NO2, Y = Br) were synthesized using the molecular hybridiza-
tion approach. The structure of these stable and crystalline
compounds was fully characterized by the usual methods (IR,
1H–, 13C–NMR) (Bernardino et al., 2006).
Fig. 1. Chemical structure of pyrazole carbohydrazides. Substituents (1) Br–NO2
(X = Br, Y = NO2); (2) NO2–Cl (X = NO2, Y = Cl) and (3) NO2–Br (X = NO2, Y = Br).
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Mice were subcutaneously infected in the left hind footpad with
1  106 promastigotes (late log phase) of L. amazonensis. The pyra-
zole carbohydrazide compounds (1.5 mg/kg/day of Br–NO2, NO2–Cl
and NO2–Br) were administered by oral route added to the drink-
ing water from the second week after infection for up to 7 weeks
post infection, continuously.2.5. Cutaneous lesion measurements
Lesion thickness was evaluated weekly by measuring the diam-
eters of both rear feet with a direct reading dial caliper (Mitutoyo,
Yokohama, Japan). The size of the lesion in millimeters was calcu-
lated by subtracting the measurement of the uninfected foot from
that of the infected foot (Charret et al., 2009). The animals were
euthanized at 12 weeks post infection.2.6. Histopathology and immunohistochemistry
Skin lesions were collected at 12 weeks of infection, and the tis-
sues were ﬁxed in buffered 4% formalin overnight and embedded
in parafﬁn. The sections (5 lm) were hydrated and stained by
Mayer hematoxylin/eosin with phloxine (Sigma–Aldrich, Massa-
chusetts, USA) staining. Amastigote forms and the cellular inﬁltra-
tion were counted on HE-stained sections from ﬁve animals/group.
The inﬂammatory inﬁltrate was graded, as follows (Solano-Gallego
et al., 2004): , no inﬂammatory inﬁltrate; +, isolated foci of
inﬂammatory cells; ++, isolated to coalescing areas of inﬂamma-
tory inﬁltrate; +++, diffuse areas of inﬂammatory inﬁltrate.
Amastigotes were evaluated semi-quantitatively in sections as
the average number in ten ﬁelds (400) in areas with inﬂamma-
tory inﬁltrate (Giunchetti et al., 2006). The results were expressed
as: , none; +, light density, (1–100); ++, moderate density (101–
300); +++, high density (>300).
For the immunostaining, sections were deparafﬁnized and trea-
ted with distilled water containing 3% H2O2 and were then un-
masked with 10 mM sodium citrate buffer in a steam bath and
blocked using a biotin blocking kit (Dako, Glostrup, Denmark).
The sections were incubated with 20% normal goat serum and,
then, with monoclonal anti-B220 (Southern Biotechnology, San
Diego, CA, USA), CD3 (DBS, Pleasanton, CA, USA), -F4/80 (AbD Sero-
tec, Kidlington, Oxford, UK) and -MPO (LifeSpan bioScience, Seattle,
WA, USA) antibodies to identify B and T lymphocytes, macrophages
and neutrophils, respectively. Peroxidase activity was detected
using the DAB substrate system (Dako, Glostrup, Denmark). Thetissue sections were analyzed by optical microscopy. Immuno-
stained cells in the dermal lesion with cellular inﬁltrate were quan-
tiﬁed by using 15 random images (total area = 1.1  106 lm2) per
section. Thus, the predominance of cells in the inﬂammatory inﬁl-
trate and their distribution within the skin layers were counted
and registered quantitatively. The images exhibited in the 40
objective were digitized through a Leica DMI3000B microscope
with a coupled camera using the program Leica Application Suite
(Leica Microsystems Ltd., Heerbrugg, Switzerland).2.7. Flow cytometry analysis
Popliteal lymph nodes were carefully removed and cleaned
from adipose tissue. Cell suspension was prepared by ﬁne mincing
the organ with needles in PBS pH = 7.2. The tissue was passed
through a nylon sieve and suspended in ice-cold PBS supplemented
with 2% heat inactivated fetal calf serum. The cell viability was
determinate by the trypan blue exclusion test. Three hundred
thousand cells were incubated for 10 min at 4 C with PBS - 2%
mixture (v/v) fetal calf serum and 1/10 diluted normal mouse ser-
um. Cells were incubated for 20 min at 4 C with optimal concen-
tration or anti-CD3.Pecy5, anti-CD4.Fitc and anti-CD8.Pe
detection of T cell subsets or anti-CD19.Pecy5 to B cells (both from
Caltag, Lab., San Francisco, CA, USA). Cells were ﬁxed with PBS-1%
formaldehyde containing 0.05% azide. Samples were acquired with
a FACS CyAn Flow Cytometer (Dako, Glostrup, Denmark). A total of
10,000 events were collected within a viable lymphocyte-enriched
gate, deﬁned according to the forward and side scattering param-
eters. Appropriate ﬂuorescence gates were created based on the
labeling controls, with respect to curve inﬂexions, and the analysis
was carried out with the Summit v.4.3 Build 2445 program (Dako,
Fort Collins, CO, USA).2.8. RT–PCR
Total RNA, obtained from lesions of three mice at 12 weeks
post-infection, was extracted using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
Next, 1 lg of total RNA obtained from the lesions or lymph nodes
was reverse transcribed using SuperScript II RNase Reverse Trans-
criptase (Invitrogen, Carlsbad, CA, USA) and oligo(dT) 15 primers
(Promega, Southampton, UK). PCR ampliﬁcation was performed
with a programmable thermal cycler (Perkin–Elmer 2400, USA).
The cDNA ampliﬁcation protocols were as follows: for TGF-b and
GAPDH, 30 cycles of 15 s at 94 C, 30 s at 60 C, and 3 min at
72 C; for IFN-c, 35 cycles of 15 s at 94 C, 30 s at 62 C, and
3 min at 72 C; and for IL-4, 35 cycles of 15 s at 94 C, 30 s at
65 C, and 3 min at 72 C. All reactions were completed with a ﬁnal
ampliﬁcation step at 72 C for 5 min. A 100-bp ladder (Invitrogen,
Carlsbad, CA, USA) was used as a size marker. cDNA was ampliﬁed
using speciﬁc primers to target the following sequences: TGF-b1
(260-bp), forward CAAGGAGACGGAATACAGGGCT, reverse GCAC
ACAGCAGTTCTTCTCTGT, IFN-c (426-bp) forward GGCTGTTTCT
GGCTGTTACTGC, reverse GACTCCTTTTCCGCTTCCTGA, IL-4 (454-
bp) forward ACGGCACAGAGCTATTGATG, reverse ATGGTGGCTCA
GTACTACGA and GAPDH (245-bp) forward GGTGAAGGTCGGTG
TGAACGGA, reverse TGTTAGTGG GGTCTCGCTCCTG. The PCR prod-
ucts were subjected to electrophoresis in a 1.7% agarose gel con-
taining 0.8 mg/mL ethidium bromide and photographed using a
Doc-Print II (Vilber Loumart, France). The PCR products were
scanned and results were expressed as cytokine/constitutive gene
GAPDH rate. Semi-quantitative analysis was performed using im-
age-analysis software (Scion Program National Institutes of Health,
Image Program; NIH, Bethesda, Maryland).
Fig. 2. Lesion measure in infected treated and untreated mice. Bars represent mean
lesion diameter for CBA mice infected with L. amazonensis (MHOM/BR/77LTB0016)
and treated with the pyrazole carbohydrazide derivatives Br–NO2 (1), NO2–Cl (2)
and NO2–Br (3) or left untreated, at 12 weeks post-infection. Treatment started at
the second week post-infection and continued up to 7 weeks post-infection (n = 5
per group). Signiﬁcant differences between infected treated and untreated mice.
⁄p < 0.05 and ⁄⁄p < 0.01 unpaired t-test.
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To assess the parasite-speciﬁc antibody titers of IgG, IgG1, IgG2a
and IgG3, 96-well assay plates were coated with L.amazonensis pro-
mastigote lysates (50 lg/mL) overnight at 4 C. Preparation of anti-
gens has been reported previously (Leon et al., 1990). Brieﬂy, log
phase L. amazonensis promastigotes were ruptured using a sonica-
tor to homogenize the antigens and centrifuged (2000g for 10 min
to 4 C). The supernatants were stored at 20 C. After blocking with
FCS, the plates were washed and incubated with individual mouse
serum samples (1:50 dilution) in triplicate for 1 h at 37 C. Next,
the plates were incubated with peroxidase-conjugated goat anti-
mouse IgG, IgG1, IgG2a and IgG3, (BD Biosciences; Franklin Lakes,
NJ, USA) for 1 h at 37 C.
The colorimetric assay was developed with 3,30,5,50-tetrameth-
ylbenzidine (TMB), according to the manufacturer’s instructions
(BD Biosciences, Franklin Lakes, NJ, USA). Reaction with TMB re-
sulted in a yellow color, and the optical density or absorbance of
light of this substrate was measured by an ELISA plate reader (An-
thos 2010, UK). The light absorbance of TMB was measured at
450 nm.2.10. Statistical analyses
The results were expressed as the arithmetic mean, accompa-
nied by the respective standard deviation. The means of the in-
fected treated and untreated mice were compared using the
Student’s t-test to all assays. Differences were considered to be sig-
niﬁcant when P < 0.05. The statistical analyses were performed
using Graph Pad Instat 2.0.3. Results
3.1. Effect of pyrazole carbohydrazide treatment on footpad lesion
progression
We have previously shown that CBA mice treated with pyrazol-
ic carbohydrazide compounds control progression of the cutaneous
lesion after infection with L. amazonensis (Charret et al., 2009). In
this study, during the clinical analysis of CBA mice infected with
L. amazonensis, we observed progressive growth in the lesions’ size
in all animals from 3 weeks post-infection up to the end of the
study. Oral treatment with pyrazolic carbohydrazide compounds
with the X = Br, Y = NO2 (compound 1), X = NO2, Y = Cl (compound
2) and X = NO2, Y = Br (compound 3) substituents promoted the
control of the of skin lesions at 1 month after treatment, when
compared with the non-treated group (Fig.2).3.2. Histopathology and immunohistochemistry of lesions of treated
and infected untreated mice
To investigate what happened in the skin lesions when the ani-
mals were treated with pyrazole carbohydrazide, histological
(Fig. 3) and immunohistochemical evaluations were performed
(Fig. 4). The slides of the foot lesion sections obtained at 12 weeks
post-infection or 1 month after treatment revealed different inten-
sities of cellular inﬂammatory inﬁltration in the infected treated
and untreated mice (Fig. 3). In addition, histopathological exami-
nation revealed that changes in the dermis were correlated with
the macroscopic size of the lesion.
In the footpad of the infected mice, macrophages containing
amastigotes within large parasitophorous vacuoles were present
at much higher numbers (Fig. 3A). Furthermore, a great number
of free parasites were detected in the dermis of these mice. Theinﬁltrating cells were a mixture of inﬂammatory cells, including
macrophages, lymphocytes, neutrophils and eosinophils.
In contrast, the all treated mice groups showed lower numbers
of parasitized macrophages (Fig. 3B, C and D) and few free amastig-
otes in the extracellular space. CBA mice infected and treated with
the pyrazole carbohydrazide derivatives had much smaller skin le-
sions, and the structures of the epidermis and dermis were pre-
served, with slighter inﬂammatory inﬁltrates (Figs. 2 and 3B–E).
Although vacuolated macrophages containing intracellular para-
sites were found in the dermis of treated animals, they were far
less numerous than in untreated animals. Infected mice treated
with compound 3 showed more parasites (Fig.3D and F) than other
treated group.
To further deﬁne the cellular populations present at the infec-
tion sites, immunohistochemical studies using speciﬁc monoclonal
antibodies for B220, CD3, MPO and F4/80 were performed. When
analyzed by optical microscopy it was observed a decreased of
B220+ cell population in the lesions of treated mice compared to
those in the untreated mice, except to animals treated with com-
pound 3. In addition, the T cell (CD3+) population remained com-
parable in the tissues of both infected treated and non-treated
mice groups although in mice treated with compound 2 this pop-
ulation was signiﬁcantly diminished (Fig. 4B). MPO+ cells were de-
tected in the tissues of both infected treated and untreated mice
groups. Vacuolated macrophages were observed by hematoxylin
and eosin staining, but when assessed by immunohistochemistry,
cells stained with anti-F4/80 monoclonal antibodies were not
clearly detected in the infected mice, treated or not. Thus, signiﬁ-
cant decrease of F4-80 expression was observed in dermal macro-
phages in treated with compounds 1 and 3 mice groups.
3.3. Evaluation of lymphoid cell populations
Leishmania amazonensis-infected CBA mice had swollen popli-
teal draining lymph nodes, and it was important to assess the sub-
populations of lymphocytes present in the lymph nodes of the
footpad. To deﬁne which cell types were present at draining lymph
nodes, ﬂow cytometry was used to determine the relative propor-
tions of B (CD19+) and T lymphocytes (CD3+) and their subsets
(CD4+ and CD8+).
The percentages of lymphocytes present in the lymph nodes of
infected and uninfected animals are displayed as histograms
Fig. 3. Histological analysis of the skin in L. amazonensis-infected mice at 12 weeks post-infection. CBA mice were infected with 1  106 promastigotes in the right hind foot
and either treated with pyrazol carbohydrazydes for 7 weeks or left untreated. Representative Hematoxilin/Eosin staining of lesion tissues from (A) infected untreated
animals. Mononuclear inﬂammatory inﬁltrate is observed in the dermis where amastigotes are within macrophage cells (arrows). (B) Animals treated with Br–NO2
(compound 1), (C) NO2–Cl (compound 2) and (D) NO2–Br (compound 3). Sections from the treated mice (B–C) showed more preserved skin containing fewer parasites. The
magniﬁcation was 400, Bar, 50 lm. (E) Dermal inﬂammation and (F) parasite burden in foot skin (white bar [], absent; grey bar [+], mild; dark bar [++], moderate; black bar
[+++], intense. Signiﬁcant differences between infected and non-infected mice. ⁄p < 0.05 unpaired t-test.
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draining lymph nodes showed a very signiﬁcant (p = 0.002) de-
crease in the relative number of CD3+ cells in infected animals rel-
ative to the uninfected control mice (data not shown). The
percentage of CD4+ cells in infected untreated mice was decreased
(p = 0.001), whereas CD8+ cells were signiﬁcantly increased
(p = 0.03) compared with the uninfected control group (Fig. 5A, B
and E). In addition, an increase in CD19+ cells (Fig. 5C, D and F)
was observed in all infected group compared with the uninfected
control group (p = 0.01). Moreover, no signiﬁcant difference was
observed in the percentages of CD3+ or CD19+ cells between the
infected treated and untreated groups.
3.4. Expression of cytokines in lymph node cells
The cytokines that mediate inﬂammatory responses were eval-
uated by RT-PCR using RNA from draining lymph node cells at the
site of the infection. The mRNA expression levels of TGF-b and IFN-
c in the draining lymph nodes were not statistically different in the
infected mice treated with compound 1 and those left untreated,
when quantiﬁed at 12 weeks post-infection. Even though theseresults showed high variability, it was remarkable that IL-4 mRNA
expression was lower (p < 0.05) in the mice treated with com-
pound 1 than in infected untreated mice (Fig. 6A and B).
3.5. IgG isotypes of anti-Leishmania antibodies
To investigate the possibility of immunomodulation, the levels
of speciﬁc anti-Leishmania antibodies were analyzed at 6 weeks
after infection. Serum levels of anti-Leishmania IgG were increased
in all infected animals treated or not and were signiﬁcantly higher
in animals treated with compound 2 (Fig. 7A). Similar levels of spe-
ciﬁc anti-Leishmania antibodies of the IgG1 subclass were observed
in the animals treated with compounds 1 and 2 (Fig. 7B). Moreover,
a signiﬁcant increase in the levels of IgG2a anti-Leishmania anti-
bodies was observed in the animals treated with compound 2,
whereas the animals treated with compound 1 showed the same
level of IgG2a antibodies as the infected untreated animals
(Fig. 7C). Speciﬁc anti-Leishmania IgG3 (Fig. 7D) levels were in-
creased in mice treated with compound 1 compared with un-
treated animals, indicating that there was an imbalance toward
the TH1 response at this time point.
Fig. 4. Immunohistochemical analysis of cutaneous lesions from mice infected with L. amazonensis at 12 weeks post-infection, with or without treatment. The mice were
grouped, infected treated and untreated as described in Fig. 2. Lesion tissues were collected and immunostaining with anti-B220, anti-CD3, anti-MPO antibodies, or anti-F4/
80. (A) Representative sections showed inﬁltrating B220+ cells. Some inﬁltrating CD3+ cells were observed. Cell staining for MPO and F4/80 was observed. All images were
taken at 400x magniﬁcation. (B) Quantiﬁcation of the immunostained cells. Cellular inﬁltrate of the cutaneous tissues were quantiﬁed by using 15 random images (total
area=1.1  106 lm2) per section. Bars represent mean immunostained cells for anti-B220, MPO, CD3 and F4-80 antibodies from ﬁve CBA mice infected with L. amazonensis
(MHOM/BR/77LTB0016) and treated with the pyrazole carbohydrazide substituents Br–NO2 (1), NO2–Cl (2) and NO2–Br (3) or left untreated. Signiﬁcant differences between
infected treated and untreated mice. ⁄p < 0.05 unpaired t-test.
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Leishmaniasis is a tropical/subtropical disease that has been
treated with a variety of drugs with toxic properties (Foti, 2001).
In this study, we demonstrated that pyrazole carbohydrazide
derivatives decrease cellular inﬁltration into the cutaneous lesions
induced by L. amazonensis infection. In a previous study, pyrazole
carbohydrazides (compound 1, X = Br, Y = NO2 and compound 2,
X = NO2, Y = Cl) had a signiﬁcant effect against the promastigote
form of L. amazonensis in vitro, although compound 3 (X = NO2,
Y = Br) showed little activity. We have shown that the substituents
on the benzene ring can strongly inﬂuence the in vitro activity(Bernardino et al., 2006). Since the search for alternative therapies,
including the identiﬁcation of formulations for the oral treatment
of cutaneous leishmaniasis, is emerging (Croft and Coombs,
2003), we decided to test the therapeutic effects of these com-
pounds. We demonstrated that oral treatment with pyrazolic car-
bohydrazides (compound 1, X = Br, Y = NO2, and compound 2,
X = NO2, Y = Cl) decreased lesion size and reduced the parasite bur-
den in the popliteal lymph nodes by approximately 98% at the 16th
week post-infection compared with the infected untreated mice
(Charret et al., 2009). Moreover, compound 3, a molecule that sub-
stitutes bromine atoms (X) for nitro (Y) on the benzene ring at the
para-position, did not show in vitro leishmanicidal activity toward
Fig. 5. Cellular proﬁles of mice uninfected, infected untreated and treated for up to 7 weeks with pyrazole carbohydrazides derivatives as assessed at 12 weeks post-infection.
The proportion of CD4+ and CD8+ T lymphocytes from the popliteal lymph node of mice (A) uninfected control and (B) infected untreated and (E) treated with pyrazole
carbohydrazides 1, 2 and 3. CD19+ B lymphocytes from the popliteal lymph node of mice (C) uninfected, (D) infected untreated and (F) treated with pyrazole carbohydrazides
1, 2 and 3. The data are presented as the mean ± S.D. for each group. (E) Untreated infected group shows signiﬁcantly to lower percentages of CD4+ (⁄p < 0.05) and higher CD8+
(p < 0.05) to uninfected control. (F) The percentages of CD19+ cells of all infected groups (untreated or treated) was signiﬁcantly higher to control uninfected (p = 0.01). There
were no signiﬁcant differences between the infected treated and untreated groups.
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current work, although this compound did show a reduction of
cutaneous lesion size, several amastigote forms in the site of infec-
tion were observed (Figs. 2, 3D and F). Additionally, a small num-
ber of studies correlated clinical responses with the in vitro
sensitivity of promastigotes in the New World (Azeredo-Coutinho
et al., 2007).
The analysis of the cellular proﬁle of the infected footpad at
12 weeks post-infection showed mainly vacuolated macrophages
ﬁlled with amastigotes (Fig. 3A). This observation was corrobo-
rated by others studies (Lemos de Souza et al., 2000; Abreu-Silva
et al., 2004; Cardoso et al., 2010). In addition, MPO+ cells were ob-
served in the lesions at 12 weeks post-infection with L. amazonen-
sis in untreated and treated mice. CBA mice infected with L.
amazonensis had an increased percentage of neutrophils in the
peripheral blood, which was not seen when infected animals were
treated with the pyrazole carbohydrazide derivatives (Charret
et al., 2009). Although pyrazolic compounds were able to control
the parasitic burden of the draining lymph node and decrease
the size of the cutaneous lesions and the extent of cellular inﬁltra-
tion at the site of infection in our study, the inﬂammatory process
observed at the site of infection was not completely eliminated; a
few intra- and extracellular parasites were still observed in the
dermis at the end of the treatment, mainly in CBA mice infected
and treated with compound 3. Therefore, the combination of some
existing drugs with these new compounds might be required to
improve the efﬁcacy of the treatment and reduce side effects. Inaddition, vacuolated macrophages were detected by hematoxylin
and eosin staining, but when evaluated by immunohistochemistry,
cells stained with anti-F4/80 monoclonal antibodies were scarcely
detected in the infected mice, treated or not. These results argue
against the frequent practice of employing F4/80 as the only sur-
face marker for identifying macrophage. The expression of F4/80
is strongly regulated according to the physiological status of cells
and F4/80 expression on Langerhans’ cells decreases after they take
up antigens and become migrating DCs (Lin et al., 2005).
In this study, an expansion of B lymphocytes and a decrease in T
lymphocytes was observed in the popliteal lymph nodes of CBA
mice infected with L. amazonensis that had been treated with pyr-
azolic carbohydrazides or left untreated. These compounds failed
to directly modulate the expansion of any particular lymphocyte
subset within the lymph node (Fig. 5E and F). Similar to another
study (Cardoso et al., 2010), our results demonstrated an expan-
sion of B cells in the draining lymph node at the site of the infection
and in cutaneous lesions from CBAmice infected with L. amazonen-
sis 12 weeks post-infection (Fig. 5D and F). Additionally, treatment
with these compounds decreased the percentage of B cells (Fig. 4)
present in the dermis of infected mice but not in the lymph nodes
(Fig. 5F). Furthermore, some studies have found that B cells play an
important role in leishmaniasis pathogenesis. (McMahon-Pratt and
Alexander, 2004), especially in the priming of Leishmania-speciﬁc
CD4+ T cells (Wanasen et al., 2008). The level of CD4+ T-cell activa-
tion could be an important factor in determining the outcome of
Leishmania infection (Xin et al., 2011).
Fig. 6. Cytokine mRNA expression in lymph node cells from Leishmania-infected
mice. Total mRNA of lymph node cells was extracted for the measurement of
cytokine expression by RT-PCR at 12 weeks post-infection. Densitometric analyses
were performed and TGF-beta, IL-4 and IFN-gamma transcripts were quantiﬁed. (A)
mRNA was normalized to the constitutive expression of GAPDH. mRNA expression
is shown for infected untreated mice (black bars) and infected animals orally
treated with compound 1 (white bars). The lower panels show the expression of
cytokines and GAPDH at 12 weeks post-infection, (B). The data represent the
mean ± SD (n = 3 mice) and statistical differences were detected by Student’s t-test.
⁄p < 0.05.
Fig. 7. Enzyme linked immunosorbent assay (ELISA) for serum antibodies to soluble antig
mice treated with compounds 1 (grey bars) and 2 (dark bars) or left untreated (black bars
IgG1, (C) IgG2a and (D) IgG3 are shown. The data are presented as the mean ± SD for each
unpaired t-test.
208 K.S. Charret et al. / Experimental Parasitology 133 (2013) 201–210In the present study, TGF-b and IFN-cmRNA expression was de-
tected by RT-PCR in the draining lymph nodes, and these results
were not statistically different for the infected treated or untreated
groups, when quantiﬁed at 12 weeks post-infection (Fig. 6). How-
ever, the mRNA expression of IL-4 was lower in mice treated with
compound 1 than in the infected untreated mice. IL-4 is considered
to be a susceptibility factor for L. amazonensis infection (Guimarães
et al., 2006).
Because of the involvement of B cells in immune responses to
Leishmania infection, their antibody products were also investi-
gated. Kima et al., 2000 showed that JhD mice that were unable
to produce antibodies were resistant to Leishmania infection with
reduced lesion size. In addition, mice lacking the FcR c chain
showed reduced inﬂammation (Barnes et al., 2002). Cytokines
secreted by T cells are also involved in the activation of B cells,
inducing antibodies with diverse isotypes. IL-4 drives IgE and
IgG1 antibody production and inhibits the production of IgG2a,
IgG2b and IgG3, whereas IFN-c stimulates IgG2a and IgG3 produc-
tion (Coffman et al. 1988). Our experiments showed that anti-
Leishmania IgG isotypes increased in all infected animals. Recently,
it has been shown that IgG1, but not IgG2a/c, was considered
pathogenic to Leishmania mexicana infection, and mice lacking
IgG1 showed increased IgG2a/c, IgG3, and IgM levels and were less
susceptible to infection (Chu et al., 2010). In our study, a signiﬁcant
increase in the levels of IgG2a anti-Leishmania antibodies was
observed in the animals treated with compound 2, whereas the
animals treated with compound 1 had increased IgG3 levels. The
speciﬁc anti-Leishmania IgG subclasses show an interesting pattern
of Th1/Th2 responses driving to humoral immune responses inen of Leishmania amazonensis. Serum from uninfected mice (white bars) and infected
) were collected at 6 weeks post-infection. Optical density (OD). Levels of (A) IgG, (B)
group. Signiﬁcant differences between infected treated and untreated mice. ⁄p < 0.05
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bohydrazides. However, Leishmania-speciﬁc antibodies could in-
crease parasite uptake by macrophages and dendritic cells and
modulate their functions (Prina et al., 2004). In addition, a study
(Deak et al., 2010) points to B cell activation as an important fea-
ture of leishmaniasis pathogenesis; this may signify a target for
therapeutic intervention.
The pyrazolic carbohydrazide compounds have no toxicity
(in vitro and in vivo) and therapeutic effect of these compounds
may be comparable with that of ketoconazole (Charret et al.,
2009). The pyrazolic carbohydrazide compounds belong to azole
class, which are able to inhibit ergosterol biosynthesis (Hitchcock
et al., 1990), although the mechanism of action of pyrazole car-
boidrazides on Leishmania is not well understood. The pyrazole
ring observed in some anti-inﬂammatory drugs could be responsi-
ble for inhibition of the ciclooxigenase (Palomer et al., 2002). This
fact could explain the reduction of B lymphocytes and macro-
phages in cutaneous lesion after treatment. Further assays will
be necessary to deﬁne the mechanism of action of pyrazole car-
boidrazides. Our results was corroborated with fact that azole in-
duced a parasite burden-correlated decrease in interleukine-4
production in the popliteal lymph node of the mouse (Pagniez
et al., 2006). Thus, studies with pyrazolic agents on leishmaniasis
should be continously investigated.
One major problem of leishmaniasis treatment is the emer-
gence of parasite resistance and toxic effects, consequently alterna-
tive drugs should be more explored. In conclusion, this report
showed that CBA mice infected with L. amazonensis and treated
with pyrazole carbohydrazide had smaller skin lesions and showed
intact structures of the epidermis and dermis with little inﬂamma-
tory inﬁltration through immunomodulation.
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